The National Health Service announced that men with early‑stage prostate cancer will soon receive stereotactic ablative radiotherapy (SABR), a high‑precision treatment that reduces the standard 20‑session course to just five visits. Sir Jim Mackey, chief executive of NHS England, said the new protocol will ease the burden on patients and free up hospital capacity , with the rollout slated to begin within weeks.

Five-session SABR to replace 20-session radiotherapy

According to the NHS press release, SABR delivers a much higher radiation dose in fewer fractions, targeting the tumour from multiple angles while sparing surrounding tissue. The five‑session schedule spans two weeks, compared with the conventional three‑week, 20‑visit regimen. Early clinical data suggest the approach may also lower the risk of recurrence, offering a dual benefit of convenience and potentially better outcomes.

48 NHS radiotherapy centres to adopt SABR within three months

The rollout plan covers all 48 radiotherapy centres in England , with some hospitals ready to start as early as next week. NHS England expects the technology to be fully operational nationwide within the next 90 days, a timeline that reflects the urgency of easing cancer waiting lists. Professor Peter Johnson, NHS National Clinical Director for Cancer, highlighted that the rapid deployment is possible because the equipment upgrades have already been funded in many trusts.

Potential 50,000 freed appointments per year

Modelling by NHS England estimates that roughly 3,500 men – out of the 17 ,500 diagnosed annually with early‑stage disease – will choose SABR , which could free up about 50 ,000 treatment slots each year. Those appointments can then be redirected to other cancer patients, helping to reduce the overall backlog that has plagued the service since the pandemic. As David James of Prostate Cancer Research noted, swift implementation is crucial to realise these system‑wide gains.

Who will decide eligibility among 17,500 diagnosed men?

Eligibility criteria remain a key point of discussion . The therapy is recommended for low‑ or intermediate‑risk prostate tumours, but clinicians caution that not every localized case is suitable. Dr Nicky Thorp of the Royal College of Radiologists emphasized that specialist teams must assess tumour size, location and patient health before recommending SABR. Patients are urged to have detailed consultations to understand whether the five‑session protocol fits their individual case.

Open question:Will SABR expand to advanced prostate cancer?

While the current rollout focuses on early disease, Amy Rylance of Prostate Cancer UK said ongoing trials aim to test SABR in more advanced stages, which could "completely shift the paradigm" of prostate cancer care. However, as of now, the NHS has not committed to broadder use, leaving the oncology community to watch for future trial results before any policy change.